The N-terminal region of centrosomal protein 290 (CEP290) restores vision in a zebrafish model of human blindness

Lisa M. Baye¹, Xiaobai Patrinostro¹, Svetla Swaminathan¹, John S. Beck²,4, Yan Zhang²,4, Edwin M. Stone³,4, Val C. Sheffield²,4 and Diane C. Slusarski¹,*

¹Department of Biology, ²Department of Pediatrics and ³Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA and 4Howard Hughes Medical Institute, Chevy-Chase, MD, USA

Received December 14, 2010; Revised and Accepted January 18, 2011

The gene coding for centrosomal protein 290 (CEP290), a large multidomain protein, is the most frequently mutated gene underlying the non-syndromic blinding disorder Leber’s congenital amaurosis (LCA). CEP290 has also been implicated in several cilia-related syndromic disorders including Meckel–Gruber syndrome, Joubert syndrome, Senor–Loken syndrome and Bardet–Biedl syndrome (BBS). In this study, we characterize the developmental and functional roles of cep290 in zebrafish. An antisense oligonucleotide [Morpholino (MO)], designed to generate an altered cep290 splice product that models the most common LCA mutation, was used for gene knockdown. We show that cep290 MO-injected embryos have reduced Kupffer’s vesicle size and delays in melanosome transport, two phenotypes that are observed upon knockdown of bbs genes in zebrafish. Consistent with a role in cilia function, the cep290 MO-injected embryos exhibited a curved body axis. Patients with LCA caused by mutations in CEP290 have reduced visual perception, although they present with a fully laminated retina. Similarly, the histological examination of retinas from cep290 MO-injected zebrafish revealed no gross lamination defects, yet the embryos had a statistically significant reduction in visual function. Finally, we demonstrate that the vision impairment caused by the disruption of cep290 can be rescued by expressing only the N-terminal region of the human CEP290 protein. These data reveal that a specific region of the CEP290 protein is sufficient to restore visual function and this region may be a viable gene therapy target for LCA patients with mutations in CEP290.

INTRODUCTION

Mutations in centrosomal protein 290 (CEP290) cause the non-syndromic blinding disorder Leber’s congenital amaurosis (LCA10, OMIM 611755) as well as several cilia-based syndromic disorders including Meckel–Gruber syndrome (MKS4, OMIM 611134), Joubert syndrome (JSTS5, OMIM 610188), Senor–Loken syndrome (SLSN6, OMIM 610189) and Bardet–Biedl syndrome (BBS14, OMIM 209900). The CEP290 protein is encoded by 54 exons, is 2479 amino acids in length and has 25 predicted protein domains, motifs and localization signals (1). Disease-causing mutations including missense, nonsense, splicing and frame shifting changes occur throughout the length of the protein (2,3). To date, no clear correlations between phenotype and the corresponding genotype have been identified between CEP290 mutations and observed diseases (2); therefore, it has been difficult to understand the precise role and the functional domains of this large protein. Moreover, although these diseases have some overlapping phenotypes, there is variability in the severity of disease states and organ involvement, which is consistent with the idea that the protein has tissue-specific roles that manifest differently based on the genotype.

*To whom correspondence should be addressed at: Department of Biology, University of Iowa, 246 Biology Building, Iowa City, IA 52242, USA. Tel: +1 3193353229; Fax: +1 3193351069; Email: diane-slusarski@uiowa.edu

© The Author 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The CEP290 protein has been shown to play a role in microtubule-associated protein transport and localizes to centrioles as well as to the connecting cilium of the photoreceptor cell (1,4). The photoreceptor is a highly polarized, light-sensing cell of the retina. The cell body, where protein synthesis occurs, is found in the outer nuclear layer and is connected to the outer segment, where phototransduction occurs, via a modified cilium called the connecting cilium. The connecting cilium transports proteins critical for development, maintenance and function of the photoreceptor from the cell body to the outer segment through the process of intraflagellar transport (5–10). Changes or disruptions in proper protein trafficking have been shown to result in photoreceptor degeneration and ultimately blindness (9,11,12). LCA is an early-onset blinding disorder in which most patients present in infancy with a lack of visual response but relatively normal retina (13–15). Mutations in CEP290 account for up to 30% of all LCA cases, and the most common CEP290 mutation accounts for ~43% of the disease-causing variations in this gene (13,15,16). This common CEP290 allele is an intronic mutation that disrupts normal splicing of the transcript resulting in a premature stop codon; however, this particular mutation is considered hypomorphic as some wild-type transcript is still present in the homozygous affected individuals (17).

Two genetic animal models are currently being used to study the role of CEP290 in vision, the rd16 mouse and the rdAc cat. The rd16 mouse possesses an in-frame deletion of amino acids 1599–1897 and presents with a severe, early-onset retinal degeneration that exhibits decreased rod and cone function by post-natal day 18 (4). The rdAc cat harbors an intronic mutation that causes an aberrant splicing of the transcript in intron 50 resulting in a truncated protein that is missing the last 159 amino acids (18). rdAc cats exhibit late-onset retinal degeneration (18). The variation in the phenotypes observed between these animal models of LCA with unique genotypes led us to examine the developmental role of cep290 relative to vision in the zebrafish system by specifically targeting a region of the cep290 gene that would model the most common human CEP290 mutation causing LCA in patients, c.2991 + 1655A > G (17). We then performed structural/functional analysis of CEP290 by testing the sufficiency of specific regions of the human CEP290 protein to suppress gene knockdown defects. Finally, we tested the ability of these regions to bind nephrophilis-2 (NPHP2), a known member of complexes in the retina proposed to affect retinal degeneration (19).

cep290 knockdown in zebrafish has been previously shown to result in several phenotypes including convergence extension defects, hydrocephalus, small eyes, kidney cysts and body curvature (1,20–22). In our targeted knockdown of cep290 in zebrafish, we observed curvature of the body axis indicative of cilia dysfunction. Mutation of CEP290 has been reported in a single individual with phenotypic features overlapping BBS (resulting in the alternative gene name BBS14). We evaluated our cep290 knockdown embryos and found that they exhibited two phenotypes shared when all bbs genes are knocked down to date (bbs1–13) in zebrafish, reduced Kupffer’s vesicle (KV) size and delayed retrograde melanosome transport (23–26) (Lisa M. Baye and John S. Beck, unpublished data). Histological examination of the developing retina in cep290 knockdown embryos revealed no gross lamination defects; however, functional analysis of vision revealed a reduction in visual behavior. Importantly, we were able to restore visual responsiveness by expressing only the N-terminal region of the human CEP290 protein in the knockdown embryos. This observation indicates that the N-terminal region of the CEP290 gene is sufficient to suppress the visual impairment and may be a viable treatment option for LCA patients.

RESULTS

cep290 is expressed throughout development in several tissues including the KV and eye

To understand the functional role of cep290 in the zebrafish, we first examined the spatial–temporal expression pattern of the gene throughout development and in adult tissues. Reverse transcriptase–polymerase chain reaction (RT–PCR) analysis revealed that the cep290 transcript is inherited maternally and is present throughout all stages of development (Fig. 1A). cep290 is also expressed in the adult zebrafish eye and, specifically, in the retina (Fig. 1A) as well as in all other tissues examined (data not shown). Whole-mount in situ hybridization at the 8-somite stage shows that the gene is ubiquitously expressed early in development (Fig. 1B and C). Of note, cep290 is present around the KV (Fig. 1D), which is a ciliated structure found transiently in the posterior tailbud and contributes to left–right patterning of the embryo (27). In 5-day post-fertilization (dpf) embryos, cep290 is found in several tissues including the brain, eye, ear, notochord and the gut region when compared with the control embryo with no antisense probe added (Fig. 1E and F). Sectioning of the 5 dpf retina revealed cep290 expression in the ganglion cell layer (GCL), portions of the inner nuclear layer (INL) as well as the photoreceptor cell layer (PR) (Fig. 1G and H).

cep290 gene targeting and gross morphology of knockdown embryos

The most common human CEP290 mutation underlying LCA is an intronic mutation, c.2991 + 1655A > G, which alters gene splicing and results in a stop at amino acid C998X (Fig. 2A) (17). We mimicked this LCA mutation in zebrafish by using an antisense Morpholino (MO) that disrupts the splicing of the zebrafish cep290 transcript at the corresponding exon 25 leading to intron inclusion (Fig. 2A, hashed bar). cep290 MO-injected embryos (morphants) exhibit body curvature defects in a MO dose-dependent manner ranging from straight to a severe C-shaped (curly) axis at 5 dpf (Fig. 2B). The curly body shape is similar to that observed in the cilia mutant seahorse, as well as in previously published cep290 exon 42-targeted knockdown zebrafish embryos (21,28). This body morphology defect is consistent with our observation that the cep290 transcript is expressed in the developing notochord (Fig. 1F). Embryos injected with the highest dose of MO (10 ng) had the greatest percentage of curly embryos (80%), whereas only 34% of embryos injected with
tissues. (A) Embryos, primers were designed to flank intron 25 (Fig. 2A). Table 1).

Figure 1. 

To verify disrupted splicing in the straight body morphant embryos, primers were designed to flank intron 25 (Fig. 2A). MO-injected embryos (8 ng dose) with a straight body axis were pooled for RNA isolation and RT–PCR was performed. Uninjected embryo cDNA amplified the expected wild-type transcript (Fig. 2C). cep290 MO-injected embryos presented a larger transcript consistent with intron inclusion (Fig. 2C). Indeed, sequence analysis of the product revealed inclusion of intron 25 which generates a frameshift that introduces a stop six amino acids past the coding amino acid 1018 in the zebrafish transcript (Fig. 2A). This aberrant transcript is present from the 8–10-somite stage through 5 dpf (Fig. 2C).

Additionally, some wild-type transcript is present in the morphant embryos, and we posit that having some wild-type transcript indeed makes this model more similar to LCA patients with the hypomorph c.2991 + 1655A > G mutation.

cep290 morphants have the cardinal zebrafish BBS phenotypes

We have previously described cilia- and transport-related defects observed with the knockdown of bbs genes in zebrafish (23–26). All bbs genes tested resulted in abnormal KV size and delayed retrograde melanosome transport in the skin pigment; therefore, we examined these cardinal features in cep290 morphant embryos (23–26).

The KV is a ciliated organ found transiently in the posterior tailbud of developing embryos from 6–15 somites (Fig. 3A). The size of the KV is assessed at the 8–12-somite stage by comparing the vesicle width to the width of the developing notochord. Embryos with a KV larger than the width of the notochord are considered normal (Fig. 3B), whereas a KV that is the same size or smaller than the width of the notochord is considered abnormal (Fig. 3C). We determined that the knockdown of cep290 results in a statistically significant percentage of embryos with abnormally sized KVs, 20.8% at the 10 ng dose, compared with 5.6% of wild-type (Fishers’s exact test, **P < 0.01; Fig. 3D). The percentage of embryos with abnormal KVs increased in a MO dose-dependent manner.

The second cardinal feature of BBS assessed in zebrafish was the rate of melanosome movement, which is a method to examine intracellular transport. Under standard conditions, zebrafish embryos adapt to their environment by trafficking their melanosomes (pigment) within the melanophores in response to light and/or hormonal stimuli (29–31). The average time of melanosome transport is assessed by treating 5 dpf dark-adapted embryos with epinephrine to chemically stimulate movement. Dark adaptation maximally disperses the melanosomes throughout the melanophore (Fig. 3E and F), whereas epinephrine treatment results in rapid retrograde movement of melanosomes to the perinuclear region (Fig. 3G) (23–26,32). Completion of melanosome transport in wild-type embryos averages 1.58 min, whereas cep290 morphant embryos at all doses showed a statistically significant delay with the 10 ng dose averaging 2.50 min (Fig. 3H, ANOVA with Tukey, **P < 0.01; Fig. 3D). Together, these data indicate that the knockdown of the cep290 transcript results in the cardinal BBS phenotypes in the zebrafish supporting a role for CEP290 in some patients with BBS.

cep290 morphants exhibit a vision defect with normal retinal lamination

To assess the role of cep290 in the developing retina, we performed histological analysis by hematoxylin and eosin (H&E) staining of morphant embryos at 3 and 5 dpf. For these analyses, we selected the moderate MO dose (8 ng) because it led to intron inclusion through 5 dpf (Fig. 2C) and displayed both the straight and the curved body axis phenotypes (Fig. 2B). We determined that regardless of body curvature, morphant embryos had a fully laminated retina at 3 dpf (Fig. 4C and D). Additionally, the photoreceptor outer
segments in the central retina revealed no overt differences compared with wild-type and control-injected embryos (Fig. 4G and H). In contrast to the parallel organization of the extending outer segments in wild-type and control-injected embryos, the extending outer segments of \textit{cep290} morphants appeared more wavy, suggesting modest disorganization at 5 dpf (Fig. 4K and L).

Since patients with LCA caused by mutations in \textit{CEP290} have been shown to present with and maintain a fully laminated retina and sparing of some photoreceptor cells yet has reduced visual perception, we sought to functionally assess vision in the \textit{cep290} morphants (14, 33). To evaluate visual function in zebrafish, we utilized a natural escape response that is elicited when embryos are exposed to rapid changes in light intensity (26, 34, 35). In the vision assay, visually responsive 5 dpf embryos change their swimming behavior when there is a short block in a bright light source (Fig. 4M–O, Supplementary Material, Movies S1 and S2). The assay is repeated five times spaced 30 s apart, and the average number of responses is reported. Wild-type embryos respond an average of 3.53 times (Fig. 6). As a control for the assay, the visually impaired \textit{cone-rod homeobox} (\textit{crx}) morphant embryos were utilized and responded only 2.00 times (Fig. 6) (26, 35). Only \textit{cep290} morphant embryos that possessed a straight body axis were used for this behavioral assay to ensure uncompromised locomotor activity (Supplementary Material, Fig. S1). In contrast to wild-type and control MO-injected embryos, \textit{cep290} morphants responded only 2.46 times during the five trials (ANOVA with Tukey, \( P < 0.01 \)). The range of responses for each experimental set of embryos is depicted in Supplementary Material, Figure S2. The majority of wild-type and control MO-injected embryos, 67 and 54\%, respectively, responded 4–5 times in the assay of five trials, whereas only 19\% of the \textit{cep290} morphants and 16\% of the \textit{crx} morphants responded as many times. These observations indicate that the \textit{cep290} morphant embryos have reduced visual activity.

N- and C-terminal truncation constructs of \textit{CEP290} localize to centrioles

Having shown that \textit{cep290} morphant embryos have overall normal retina histology but still present with a vision defect,
we next used this vision assay to functionally identify regions of the CEP290 protein that are sufficient to suppress the vision defect. Indeed, if a smaller portion of this protein is sufficient to restore vision, then it alone could be used for gene therapy in patients using the standard retroviral techniques that are currently available. We, therefore, divided the human CEP290 gene into an N-terminal fragment that represents the first 1059 amino acids of the protein (Fig. 5A, blue) and a C-terminal fragment, amino acids 1765–2479 (Fig. 5A, green). Both of these constructs contain regions that have previously been shown to form multimers by homodimerization (21). The N-terminal construct extends over the region where the most common LCA mutation is found (noted in Fig. 5A). The C-terminal construct contains a large portion of the predicted myosin-tail domain of CEP290 that has been hypothesized to play a vision-specific role as this region is partially deleted in the rd16 mouse model of retinal degeneration (deletion of amino acids 1599–1897) (4). Additionally, this construct covers the entire region that is truncated in the rdAc cat model of late-onset retinal degeneration (18).

We first evaluated expression and localization of the human CEP290 N- and C-terminal constructs in zebrafish. mRNA encoding myc-tagged fusion constructs were injected into zebrafish embryos and immunohistochemistry was performed. Immunostaining using anti-myc antibody revealed the expression of the constructs at 50% epiboly [≏6 hpf (hours post-fertilization); Fig. 5B and E]. Since full-length CEP290 localizes closely with the centrioles in tissues and cell lines (1,4), zebrafish centrin fused to green fluorescent protein (eGFP) was co-injected as a marker for the centriole (Fig. 5C, F and I). With both the N-terminal and the C-terminal constructs, we observed some paracentriolar as well as cytoplasmic localization (Fig. 5D and G). To verify the localization of the proteins in ciliated cells, we expressed the N-terminal and the C-terminal constructs in undifferentiated and ciliated ARPE-19 cells and found both constructs to be paracentriolar (Supplementary Material, Figs S3 and S4).

**N-terminal region sufficient to rescue the vision defect**

We next assessed if the human constructs can function in zebrafish to rescue the MO-induced vision defect. Embryos co-injected with cep290 MO and the mRNA encoding myc-tagged N- and C-terminal constructs were grown to 5 dpf. Again, only morphant embryos with a straight body axis were used in the vision assay to ensure proper embryo motility (Supplementary Material, Fig. S1). In the vision assay, cep290 morphant embryos responded on average 2.46 times, whereas morphant embryos injected with the N-terminal CEP290 construct responded 3.48 times (Fig. 6). This response was statistically the same as the wild-type response of 3.53, indicating the rescue of the MO-induced vision defect. The number of cep290 morphant embryos injected with the N-terminal cep290 construct that now responded 4–5 times in the assay rose to 53% from 19% in the MO alone (Supplementary Material, Fig. S2). Conversely, injection of the C-terminal construct was unable to rescue the vision defect (Fig. 6; ANOVA with Tukey, **P < 0.01). Neither the N-terminal nor the C-terminal construct was sufficient to rescue the KV size defect and only

**Figure 3.** cep290 gene knockdown results in zebrafish BBS cardinal features. (A) Side view of a 10-somite embryo highlighting the location of the ciliated KV (circle) in the tailbud. (B and C) Dorsal views of an average-sized KV and an abnormally reduced in KV size, respectively, (arrow heads) at the 10-somite stage. The notochord is marked with an ‘N’. Embryos were scored has having an abnormal KV if the vesicle was less than the width of the notochord. (D) The percentage of wild-type, control-injected and cep290 morphant embryos with abnormal KVs. MO concentration and the number of embryos (n) are noted on the x-axis. "P < 0.01, Fisher’s exact test when compared with wild-type. (E) Dorsal view of the head melanocytes of a 5 dpf dark-adapted wild-type embryo. The boxed region represents the zoomed region for F and G. (F) Dark-adapted melanocytes prior to epinephrine treatment note the dispersed melanosomes. (G) The end point, perinuclear localization of melanosomes, after epinephrine treatment. (H) Epinephrine-induced retrograde transport times for wild-type, control-injected and cep290 morphants. MO concentration and the number of embryos (n) are noted on the x-axis. "P < 0.05, "P < 0.01, ANOVA with Tukey when compared with wild-type.
the C-terminal construct showed a suppression of the melanosome transport delay (Table 2). Taken together, these data indicate that the N-terminal region of the human CEP290 gene is sufficient to rescue the cep290 MO-induced vision defect. Additionally, because the N-terminal region cannot rescue KV and melanosome transport defects, this indicates that other regions of the protein are needed for these cellular functions.

**DISCUSSION**

CEP290 has been associated with several cilia-related diseases, but the precise functional domains of the protein and their role in normal development need to be determined. We observed that the cep290 transcript is present throughout all stages of zebrafish embryo development and is enriched in the KV region as well as in ganglion cells, the INL and photoreceptor cells of the retina. Using a targeted knockdown strategy to model the most common CEP290 mutation in LCA patients, we found body curvature defects, KV size reduction, delayed retrograde melanosome transport and vision impairment. We determined by using truncated CEP290 constructs that the N-terminal region of the CEP290 protein is sufficient to rescue the vision defect observed in cep290 knockdown embryos. Finally, we determined that this N-terminal region of the protein, but not the C-terminal region, can bind NPHP2.

LCA patients with the c.2991 +1655A > G mutation are hypomorphic in that some wild-type transcript is present in
homozygous carriers (17). It is thought that these patients present with non-syndromic LCA because there is enough wild-type transcript present that other organ systems are unaffected (17). Consistent with this hypothesis, we observe that the penetrance of the curly body axis, as well as the severity of the KV defect and melanosome transport delay, is MO dose-dependent. We also show that although the splice-block MO does induce an intron inclusion, there is still some wild-type transcript present (Fig. 2C). Due to the lack of a CEP290 antibody that specifically recognizes the endogenous full-length or the N terminus of the protein in zebrafish, we cannot determine if the truncated protein is expressed from this aberrantly spliced transcript. However, since MO-injected embryos that do not show the curly body axis still have visual impairment, it is likely that levels of cep290 are sufficient for normal axis development but are not sufficient for normal visual function.

Our finding that the expression of only the N-terminal region of the CEP290 protein is sufficient to rescue the vision defect suggests that domains within this region are able to interact with their retina-specific binding partners to allow visual function. The ability of the N-terminal region of the human CEP290 to rescue the vision defect observed in cep290 knockdown zebrafish embryos appears to be inconsistent with two existing animal models, the rd16 mouse and the rdAc cat. Mutations in these model systems are found in the C-terminal region, suggesting that it is this region of the protein that is required for vision. Possible explanations for this inconsistency include that the mutant Cep290 protein in the mouse and cat models is unstable and degraded, folds in such a manner as to affect the structure of the N-terminal region resulting in alteration of binding properties or results in changes in protein localization. It has been shown in rd16 mice that there is a reduced amount of the mutant Cep290 protein; moreover, the mutant Cep290 protein has a higher than normal affinity for RPGR, and the RPGR protein aberrantly localizes to the photoreceptor inner segment (4).

In human patients, there are several mutations found within the N-terminal region of CEP290 that result in LCA, including the mutation modeled in our study (2,3,16,17). This human mutation analysis suggests that regions outside that of the C terminus have a role in regulating binding to interacting proteins required for proper vision. The identification of NPHP protein complexes that interact with proteins known to affect vision has highlighted a molecular pathway to be further investigated for its role in the retina (19). Here, we have found that NPHP2 binds to only the N-terminal fragment of CEP290, which rescues the vision defect, but not the C-terminal construct, which suppresses the melanosome transport delay. This differential binding to restore individual phenotypes is an example of tissue specificity of protein function and highlights the importance of examining molecular pathways in a tissue-specific manner. Together, these ideas corroborate a hypothesis by Murga-Zamalloa et al. (19), in which the authors pose that the severity of a disease phenotype is the result of the degree to which individual complexes are disrupted.
such as the entire coding region (38), the functional characterization of a smaller portion of this protein sufficient to restore vision provides valuable information that can be used for potential treatments of LCA patients. Finally, we have begun to examine interacting partners with CEP290 to determine how this shortened construct is able to functionally rescue vision. We have shown that NPHP2, a known component of an identified protein complex in the retina, can bind the N-terminal construct that rescues the vision defect but not the C-terminal piece. Future work will be focused on elucidating the mechanism by which the N-terminal region of CEP290 functions within the retina.


defect but not the C-terminal piece. Future work will be focused on elucidating the mechanism by which the N-terminal region of CEP290 functions within the retina.

MATERIALS AND METHODS

Animal care
Zebrafish embryos were collected from natural spawning and maintained under standard conditions (39). Embryos were developmentally staged as described previously (40).

Reverse transcriptase–polymerase chain reaction
RNA was extracted from pools of wild-type embryos at the following stages: 1–128 cells (maternal stage), 8–10 somites, 48 hpf and 5 dpf, as well as the adult retina and whole eye. cDNA was synthesized using oligo-dT primers. Gene expression was evaluated using the following primers whose location in the cep290 gene is depicted in Figure 2A. β-actin expression served as a control.

cel290—primer F1: 5′-GGACAGGCTTTCGAAAACA-3′
cel290—primer R1: 5′-GGACAGGCTTTCGAAAACA-3′

Whole-mount in situ hybridization
A large 5′ segment of the zebrafish cep290 open reading frame (Ensemble v8: ENSDART00000090921) was TA cloned into PCRII vector (Invitrogen) from a multistage pool of embryo-

MO knockdown
The antisense splice site MO was designed and purchased from Gene Tools. The MO was air pressure injected into 1–4-cell embryos at concentrations ranging from 5 to 10 ng. The efficiency of transcript knockdown was assessed by RT–PCR (described above) using cDNA generated from pools of cep290 morphants with only the straight body axis phenotype at the following stages: 8–10 somites, 48 hpf and 5 dpf.

Standard control MO: 5′-CCTTTACCTCGGTCTGACATG-3′

cep290 MO: 5′-TTGATGTGTACCAGTTGTGC-3′
**Analysis of KV size and melanosome transport time**

The KV size was assessed on live embryos between the 6–12-somite stages of development as described previously (23). Embryos with a KV smaller than the width of the notochord were recorded as abnormal. The melanosome transport assay was performed as described previously (23). Briefly, 5 dpf dark-adapted embryos were treated with epinephrine (500 μg/ml, Sigma E4375), and the quantity of time that it took the melanosomes to traffic from the periphery of the cell to their perinuclear location was recorded. Embryos were imaged live using a stereoScope with a Zeiss AxioCam camera.

**Histological analysis**

To minimize the pigmentation of the retinal pigmented epithelium in order to view the outer segments of the photoreceptor cells, embryos were maintained in 0.03% phenylthiourea beginning at 80% epiboly and then fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS). Gross morphology of the retinas was evaluated with standard H&E staining.

**Vision startle response assay**

The vision-evoked startle-response behavioral assay was performed as described previously (26,34,35). In brief, 5 dpf zebrafish embryos were light adapted, and the visual stimulus of a 1 s block in bright light intensity was performed under a dissecting microscope. A positive visual response was recorded if the embryo made an abrupt change in swimming behavior within 1 s of the light intensity change. Five trials were performed spaced 30 s apart followed by the mechanical stimulus of probing embryos with the tip of a blunt needle. Embryos that did not respond to the mechanical stimulus were not included in the analysis.

**DNA constructs**

The fragments encoding the N-terminal (1–1059 amino acids) and the C-terminal regions (1765–2479 amino acids) of human wild-type CEP290 (NCBI Reference Sequence: NG_008417.1) were amplified from human retina cDNA (Clonetech), TA cloned into the Gateway vector system (Invitrogen), and sequence confirmed. Subsequently, the genes were recombined into gateway expression vectors with an N-terminal 6× myc tag. Embryos did not respond to the mechanical stimulus were not included in the analysis.

**SUPPLEMENTARY MATERIAL**

Supplementary Material is available at HMG online.

**ACKNOWLEDGEMENTS**

We thank Dr Caren Norden (University of Cambridge) for the gift of the zebrafish centrin fused to eGFP and Dr Darryl Nishimura and Dr Qihong Zhang (University of Iowa) for their technical expertise.
Conflict of Interest statement. None declared.

FUNDING
This work was supported by the National Institute of Health [R01CA112369 to D.C.S., R01EY110298 and R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Foundation; the Roy J. Carver Charitable Trust; the Foundation Fighting Blindness; Research to Prevent Blindness; and an Iowa Cardiovascular Center Institutional Research Fellowship [T32HL0712135 to L.M.B.]. V.C.S. and E.M.S. and an Iowa Cardiovascular Center Institutional Research Foundation Fighting Blindness; Research to Prevent Blindness; R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Health [R01CA112369 to D.C.S., R01EY110298 and
This work was supported by the National Institute of
FUNDING
Conflict of Interest statement. None declared.

FUNDING
This work was supported by the National Institute of Health [R01CA112369 to D.C.S., R01EY110298 and R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Foundation; the Roy J. Carver Charitable Trust; the Foundation Fighting Blindness; Research to Prevent Blindness; and an Iowa Cardiovascular Center Institutional Research Fellowship [T32HL0712135 to L.M.B.]. V.C.S. and E.M.S. and an Iowa Cardiovascular Center Institutional Research Foundation Fighting Blindness; Research to Prevent Blindness; R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Health [R01CA112369 to D.C.S., R01EY110298 and
This work was supported by the National Institute of
FUNDING
Conflict of Interest statement. None declared.

FUNDING
This work was supported by the National Institute of Health [R01CA112369 to D.C.S., R01EY110298 and R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Foundation; the Roy J. Carver Charitable Trust; the Foundation Fighting Blindness; Research to Prevent Blindness; and an Iowa Cardiovascular Center Institutional Research Fellowship [T32HL0712135 to L.M.B.]. V.C.S. and E.M.S. and an Iowa Cardiovascular Center Institutional Research Foundation Fighting Blindness; Research to Prevent Blindness; R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Health [R01CA112369 to D.C.S., R01EY110298 and
This work was supported by the National Institute of
FUNDING
Conflict of Interest statement. None declared.

FUNDING
This work was supported by the National Institute of Health [R01CA112369 to D.C.S., R01EY110298 and R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Foundation; the Roy J. Carver Charitable Trust; the Foundation Fighting Blindness; Research to Prevent Blindness; and an Iowa Cardiovascular Center Institutional Research Fellowship [T32HL0712135 to L.M.B.]. V.C.S. and E.M.S. and an Iowa Cardiovascular Center Institutional Research Foundation Fighting Blindness; Research to Prevent Blindness; R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Health [R01CA112369 to D.C.S., R01EY110298 and
This work was supported by the National Institute of
FUNDING
Conflict of Interest statement. None declared.

FUNDING
This work was supported by the National Institute of Health [R01CA112369 to D.C.S., R01EY110298 and R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Foundation; the Roy J. Carver Charitable Trust; the Foundation Fighting Blindness; Research to Prevent Blindness; and an Iowa Cardiovascular Center Institutional Research Fellowship [T32HL0712135 to L.M.B.]. V.C.S. and E.M.S. and an Iowa Cardiovascular Center Institutional Research Foundation Fighting Blindness; Research to Prevent Blindness; R01EY017168 to V.C.S. and E.M.S.]; the Grousbeck Family Health [R01CA112369 to D.C.S., R01EY110298 and
This work was supported by the National Institute of


